PHASE I TRIAL OF AMINOPTERIN IN PATIENTS WITH REFRACTORY MALIGNANCIES

这项研究的目的是(1)建立定性和定量的 氨基喋呤对儿童和成人的定量毒性，(2) 确定急性剂量限制毒性和恢复时间(S)， (3)确定是否有蓄积毒性；(4)确定 导致可耐受毒性的氨基喋呤最大耐受量 它是可预测和可逆的，可以用于第二阶段试验， (5)确定所需的亚叶酸钙的最小抢救剂量 以防止过度混乱，以及(6)确定预防措施和 应该使用的支持性治疗。

The purpose of this study is (1) to establish the qualitative and quantitative toxicity of aminopterin in children and adults, (2) to determine the acute dose-limiting toxicities and time(s) to recovery, (3) to determine if there is cumulative toxicity, (4) to establish a maximum-tolerated dose of aminopterin that results in tolerable toxicity which is predictable and reversible and can be used in phase II trials, (5) to determine the minimal amount of leucovorin rescue that is needed to protect from excessive tosicity, and (6) to determine precautions and supportive therapy that should be used.